Posted by Michael Wonder on 04 Sep 2017
US biotech Kite set to be first to launch one-time cancer gene therapy in Britain
3 September 2017 - US biotech Kite is expected to be first out of the blocks in Britain to launch a one-time genetic treatment for a type of cancer, in a global market expected to hit $54bn (£41.6bn) in value.
The first so-called CAR-T treatment, developed by Swiss giant Novartis with British firm Oxford BioMedica, was approved for a type of leukaemia by US regulators last week and heralded by scientists as the start of a new era in cancer treatments.
Kite, which has also recently accepted a $12bn takeover offer by rival Gilead, is understood to be planning to engage with British drug pricing agency NICE this winter ahead of launching its own CAR-T treatment here as early as next summer.
